Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07282600 · ClinicalTrials.gov registry record · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,035
- Enrollment target
- 20
- Study locations
NCT07282600: Recruiting Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT07282600 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,035 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07282600, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,035 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eloralintide
Study Locations (20)
California
- San Fernando Valley Health Institute - Canoga Park
- AMCR Institute - Escondido
- NorCal Medical Research, Inc - Greenbrae
- Inglewood Clinical - Inglewood
- Ark Clinical Research - Long Beach
- Pacific Clinical Studies - Los Alamitos
- Care Access - Santa Clarita - Santa Clarita
- Encompass Clinical Research - Spring Valley
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- Arrow Clinical Trials - Daytona Beach
- Care Access - Delray Beach - Delray Beach
- Fleming Island Center for Clinical Research - Fleming Island
- Nature Coast Clinical Research - Inverness - Inverness
- Jacksonville Center for Clinical Research - Jacksonville
Alabama
- Birmingham Clinical Research - Birmingham
- Cullman Clinical Trials - Cullman
Connecticut
- New England Research Associates, LLC - Bridgeport
- CMR of Greater New Haven, LLC - Hamden
Arizona
- Tucson Clinical Research Institute - Tucson
Colorado
- Care Access - Aurora - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,035 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2028-02 |
| Phase | Phase 3 |
What NCT07282600 shows while recruiting
NCT07282600 is an interventional study that assigns participants to a tested intervention. Its 1,035 participants enrollment target places it among the larger protocols in the corpus, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% higher).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07282600 names 20 study sites across 6 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT07282600 about?
NCT07282600 is a clinical study titled "A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes". The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
What is the current status of trial NCT07282600?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,035 participants. The study started on 2025-12-15. Estimated completion is 2028-02.
What conditions does trial NCT07282600 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07282600?
The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG).
Who is sponsoring clinical trial NCT07282600?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07282600 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07282600's enrollment target sits among peer trials
1,035 70th of 1053 higher than 984 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07345767 · 1,038 participants · NA
Hypknowledge Nationwide Sleep Extension
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI